Detalhe da pesquisa
1.
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Mol Cancer
; 14: 27, 2015 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25645078
2.
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
Mol Cancer
; 13: 194, 2014 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25142146
3.
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.
Proc Natl Acad Sci U S A
; 107(46): 20021-6, 2010 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21030678
4.
Modulating Temporospatial Phosphate Equilibrium by Nanoparticulate Mineralized Collagen Materials Induces Osteogenesis via PiT-1 and PiT-2.
Adv Healthc Mater
; 12(17): e2202750, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36863404
5.
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma.
Mol Cancer
; 14: 128, 2015 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26134498
6.
Assessing patient satisfaction among ABHRS surgeons: Opportunities to improve.
J Cosmet Dermatol
; 19(2): 462-465, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31134743
7.
Nanoparticulate mineralized collagen glycosaminoglycan materials directly and indirectly inhibit osteoclastogenesis and osteoclast activation.
J Tissue Eng Regen Med
; 13(5): 823-834, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30803152
8.
Osteoprotegerin reduces osteoclast resorption activity without affecting osteogenesis on nanoparticulate mineralized collagen scaffolds.
Sci Adv
; 5(6): eaaw4991, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31206025
9.
Differences in surgical outcomes for patients with craniosynostosis in the US: impact of socioeconomic variables and race.
J Neurosurg Pediatr
; 17(1): 27-33, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26407174
10.
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Clin Cancer Res
; 20(13): 3446-57, 2014 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24812408
11.
Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
Neoplasia
; 14(8): 757-70, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22952428
12.
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.
Anticancer Agents Med Chem
; 11(8): 729-38, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21707497
13.
Gene therapy and targeted toxins for glioma.
Curr Gene Ther
; 11(3): 155-80, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21453286
14.
B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.
Neoplasia
; 13(10): 947-60, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22028620
15.
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
Clin Cancer Res
; 15(19): 6113-27, 2009 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19789315
16.
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
Clin Cancer Res
; 15(13): 4401-14, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19570774